Fig. 7: Determinants of response to CDK2 inhibitors. | Nature Communications

Fig. 7: Determinants of response to CDK2 inhibitors.

From: Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle

Fig. 7

A DrugZ analysis from HCC1806 and MIA PaCa-2 cells to indicate the negatively selected genes following the selection with INX-315. B Live cell imaging to monitor the proliferation of HCC1806, MIA PaCa-2 and 3226 cells following RNAi-mediated FOXM1 depletion in the absence and presence of INX-315. Statistical significance was compared between siNT+INX-315 and siFOXM1+INX-315. C Effect of PF-07104091 on the proliferation of 3226 and HCC1806 cell lines following the depletion of FOXM1. Error bars were determined based on mean and SD from triplicates. Statistical significance was compared between siNT+PF-07104091 and siFOXM1+PF-07104091. D Live cell imaging to monitor the proliferation of HCC1806, MIA PaCa-2 and 3226 cells following CCNB1 depletion in the absence and presence of INX-315. Statistical significance was compared between siNT+INX-315 and siCCNB1+INX-315. E Impact of CCNB1 depletion on the cellular response to PF-07104091 in 3226 and HCC1806 cell lines. Statistical significance was compared between siNT+PF-07104091 and siCCNB1+PF-07104091. F Live cell imaging to monitor the proliferation of HCC1806 and MIA PaCa-2 cells following CDK1 depletion in the absence and presence of INX-315. Statistical significance was compared between comparing siNT+INX-315 and siCDK1+INX-315. G Cell cycle analysis in MIA PaCa-2 cells to determine the impact of FOXM1, CCNB1 and CDK1 depletion in modulating the response to INX-315. All the data are presented as mean and SD from n = 3 technical replicates. Experiments were performed at n = 3 independent times. *** represents p value < 0.0001 as determined by 2-way ANOVA for B–F. Source data are provided as a source data file.

Back to article page